Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in Pediatric IBD (VEDOKIDS)
NCT02862132Completed
- Sponsor
- Shaare Zedek Medical Center
- Start
- Jan 2017
- Primary completion
- Jan 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Open-label trial of vedolizumab in Crohn's disease, ulcerative colitis (UC) and inflammatory bowel disease (IBD), sponsored by Shaare Zedek Medical Center. Primary endpoint: Complete remission at 162 weeks. Started Jan 2017; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02862132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862132.